Congestive Heart Failure (CHF)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Congestive Heart Failure

MalaCards integrated aliases for Congestive Heart Failure:

Name: Congestive Heart Failure 12 75 29 6 15 38 17 72 33
Heart Failure 44 72
Cardiac Failure Congestive 12
Congestive Heart Disease 12
Heart Failure Congestive 55
Weak Heart 12
Chf 12


External Ids:

Disease Ontology 12 DOID:6000
ICD9CM 35 428 428.0 428.9
MeSH 44 D006333
NCIt 50 C3080 C50577
SNOMED-CT 68 42343007 84114007
ICD10 33 I50 I50.0 I50.9
UMLS 72 C0018801 C0018802

Summaries for Congestive Heart Failure

Disease Ontology : 12 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.

MalaCards based summary : Congestive Heart Failure, also known as heart failure, is related to peripartum cardiomyopathy and pulmonary edema, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Congestive Heart Failure is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Cardiac conduction. The drugs Amiloride and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include Adipose and Lateral Plate Mesoderm, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 75 Heart failure (HF), also known as congestive heart failure (CHF) and congestive cardiac failure (CCF),... more...

Related Diseases for Congestive Heart Failure

Diseases related to Congestive Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1375)
# Related Disease Score Top Affiliating Genes
1 peripartum cardiomyopathy 33.3 TTN MYH7 ACE
2 pulmonary edema 33.2 REN NPPB NPPA EDN1 ACE
3 cardiac arrest 33.1 NPPB MYH7 ACE
4 congenital hepatic fibrosis 33.1 REN AGTR1
5 orthostatic intolerance 33.1 EDN1 AGTR1 ADRB1 ADRA2C
6 cardiomyopathy, familial hypertrophic, 1 32.6 TTN MYH7 MYH6
7 mitral valve insufficiency 32.5 NPPB NPPA ACE
8 hypertensive heart disease 32.4 NPR1 NPPB AGTR1 ACE
9 sleep apnea 32.1 REN NPPB EDN1 ACE
10 angina pectoris 32.0 NPPB EDN1 ACE
11 heart valve disease 32.0 REN NPPB NPPA ACE
12 central sleep apnea 32.0 NPPB NPPA
13 systolic heart failure 31.9 NPPB EDN1 ADRB1 ACE
14 atrial fibrillation 31.9 NPPB NPPA AGTR1 ADRB1 ACE
15 mitral valve disease 31.9 NPPA AGTR1 ACE
16 atrial standstill 1 31.8 TTN NPPB MYH7 MYH6 ADRB1 ACE
17 pure autonomic failure 31.8 REN NPPA ACE
18 pericardial effusion 31.7 REN NPPB NPPA
19 diastolic heart failure 31.7 NPPB NPPA AGTR1 ACE
20 pulmonary hypertension 31.6 REN NPPB NPPA EDN1 ADM ACE
21 chagas disease 31.6 NPPB ADRB1 ACE
22 syncope 31.6 TTN NPPB NPPA
23 vascular disease 31.5 REN KNG1 EDN1 ACE
24 hypertrophic cardiomyopathy 31.5 VCL TTN MYH7 MYH6 ACE
25 anterolateral myocardial infarction 31.4 NPPB NPPA ACE
26 arteries, anomalies of 31.4 REN NPPB KNG1 EDN1 AGTR1 ACE
27 aortic valve disease 1 31.3 REN NPPB ACE
28 aortic coarctation 31.3 EDN1 AGTR1 ADRB1 ACE
29 syndrome of inappropriate antidiuretic hormone 31.3 NPPB NPPA ACE
30 restrictive cardiomyopathy 31.3 TTN NPPB MYH7
31 coronary artery anomaly 31.2 NPPB NPPA KNG1 EDN1 AGTR1 ADRB1
32 heart disease 31.2 TTN REN NPPB NPPA MYH7 MYH6
33 kidney disease 31.2 REN NPPB NPPA EDN1 AGTR1 ADM
34 tetralogy of fallot 31.2 REN NPPB NPPA EDN1
35 coronary heart disease 1 31.2 NPPB CDKN2B-AS1 ADRB1 ACE
36 pulmonary hypertension, primary, 1 31.2 NPPB NPPA EDN1 ADM
37 aortic valve disease 2 31.1 REN NPPB NPPA MYH7 ACE
38 hypoplastic left heart syndrome 31.1 NPPB NPPA MYH6
39 arteriosclerosis 31.1 EDN1 ADM ACE
40 anuria 31.0 REN AGTR1 ACE
41 hypoaldosteronism 30.9 REN NPPA ACE
42 muscle hypertrophy 30.9 NPPA MYH7 MYH6 EDN1
43 hypertension, diastolic 30.9 REN ACE
44 raynaud phenomenon 30.9 EDN1 AGTR1 ADRA2C
45 angioedema 30.8 MME KNG1 ACE
46 renal artery disease 30.8 REN AGTR1 ACE
47 acute myocardial infarction 30.7 NPPB NPPA EDN1 CDKN2B-AS1 AGTR1 ADRB1
48 familial hypertension 30.7 REN NPPA AGTR1
49 idiopathic edema 30.7 NPPB NPPA EDN1 ADM ACE
50 hypertensive encephalopathy 30.7 REN ACE

Graphical network of the top 20 diseases related to Congestive Heart Failure:

Diseases related to Congestive Heart Failure

Symptoms & Phenotypes for Congestive Heart Failure

UMLS symptoms related to Congestive Heart Failure:

tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Congestive Heart Failure:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ADM ADRA2C ADRB1 AGTR1 EDN1
2 homeostasis/metabolism MP:0005376 9.97 ACE ADM ADRA2C ADRB1 AGTR1 EDN1
3 mortality/aging MP:0010768 9.73 ACE ADM ADRA2C ADRB1 AGTR1 EDN1
4 muscle MP:0005369 9.32 ADM ADRB1 EDN1 MYH6 MYH7 NPPA

Drugs & Therapeutics for Congestive Heart Failure

Drugs for Congestive Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 999)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Etanercept Approved, Investigational Phase 4 185243-69-0
Insulin Lispro Approved Phase 4 133107-64-9
Deferiprone Approved Phase 4 30652-11-0 2972
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Zopiclone Approved Phase 4 43200-80-2 5735
Tirofiban Approved Phase 4 144494-65-5 60947
Pancrelipase Approved, Investigational Phase 4 53608-75-6
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
Cefazolin Approved Phase 4 25953-19-9 656510 33255
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Glyburide Approved Phase 4 10238-21-8 3488
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Pantoprazole Approved Phase 4 102625-70-7 4679
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
Fenofibrate Approved Phase 4 49562-28-9 3339
Ramipril Approved Phase 4 87333-19-5 5362129
Doxazosin Approved Phase 4 74191-85-8 3157
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
Manidipine Approved, Investigational Phase 4 89226-50-6
Desflurane Approved Phase 4 57041-67-5 42113
Magnesium citrate Approved Phase 4 3344-18-1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
38 Apricot Approved Phase 4
Ibuprofen Approved Phase 4 15687-27-1 3672
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
Trandolapril Approved Phase 4 87679-37-6 5484727
Magnesium oxide Approved Phase 4 1309-48-4 14792
Terbutaline Approved Phase 4 23031-25-6 5403
Ledipasvir Approved Phase 4 1256388-51-8 67505836

Interventional clinical trials:

(show top 50) (show all 6414)
# Name Status NCT ID Phase Drugs
1 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
2 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
3 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
4 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
5 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
6 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
7 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
8 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
9 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
10 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
11 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
12 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
15 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
16 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
17 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
18 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
19 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
20 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
21 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
22 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
23 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
24 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
25 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
26 Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure Unknown status NCT03255044 Phase 4 Atorvastatin;Rosuvastatin
27 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
28 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
29 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
30 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
31 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
32 Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
33 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
34 The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial Unknown status NCT01942109 Phase 4 Furosemide;Torasemide
35 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
36 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
37 A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects. Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
38 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor Unknown status NCT01156207 Phase 4 Aliskiren
39 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
40 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
41 Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study Unknown status NCT03209180 Phase 4 CarVeDilol-SR (Slow Release);Carvedilol IR (Immediate Release)
42 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
43 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
44 Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline
45 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study Unknown status NCT02963597 Phase 4
46 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
47 Remission From Stage D Heart Failure (RESTAGE-HF) Unknown status NCT01774656 Phase 4 Pharmacological Treatment
48 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
49 Effectiveness of Inspiratory Muscle Training Associated With a Cardiac Rehabilitation Program in Sympathetic Activity and Functional Capacity in Patients With Heart Failure: a Randomized Clinical Trial Unknown status NCT02600000 Phase 4
50 The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve. Unknown status NCT01368575 Phase 4

Search NIH Clinical Center for Congestive Heart Failure

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Benazepril hydrochloride
Bisoprolol Fumarate
candesartan cilexetil
carvedilol phosphate
Chlorothiazide sodium
coenzyme Q10
Digitalis preparation
Enalapril Maleate
Eprosartan mesylate
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam Mesylate
Fosinopril Sodium
Growth Hormone
Hydralazine Hydrochloride
inamrinone lactate
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol hydrochloride
Losartan Potassium
metoprolol succinate
Metoprolol Tartrate
Milrinone Lactate
Moexipril hydrochloride
Olmesartan medoxomil
Perindopril arginine
Perindopril Erbumine
Propranolol Hydrochloride
Quinapril hydrochloride
Sodium Nitroprusside
Timolol Hemihydrate
Timolol Maleate

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Congestive Heart Failure cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Congestive Heart Failure:
ACP-01, autologous angiogenic precursor cells for cardiac diseases
Adipose-derived stem cells for treatment of congestive heart failure
BMAC, autologous bone marrow aspirate concentrate for congestive heart failure
Bone marrow-derived adult mononuclear cells for heart diseases
Cardiac progenitor cells for single-ventricle anomalies
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
C-Cure, mesenchymal stem cell-derived cardiomyocytes for heart failure
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
CD34+ stem cells for treatment of congestive heart failure
Enriched bone marrow-derived progenitor cells for heart diseases
ERCs, endometrial regenerative cells for congestive heart failure
Human cardiac-derived stem cell for the treatment of congestive heart failure
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
MyoCell, muscle stem cells for severe heart damage
Peripheral or bone marrow-derived stem cells for chronic heart failure
Embryonic/Adult Cultured Cells Related to Congestive Heart Failure:
Angiogenic cell precursors
Adipose-derived mesenchymal stem cells (family)
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 18351022 23788089 15995108
Bone marrow-derived mononuclear cells PMIDs: 20524773 20445812 19699857 22137069
Cardiac progenitor cells PMIDs: 17502484 14530411 18754813
Cardiac stem cells PMIDs: 17502484 14530411 18754813
Cardiosphere-derived cells PMIDs: 22336189
Cardiomyocyte-like cells PMIDs: 18835562 23583247
Bone marrow-derived CD133+ cells PMIDs: 17320570
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 23362308 16990384 18794392 22936827
Endometrial regenerative cells PMIDs: 18005405 23510656 20398245 19232091
Human cardiac stem cells PMIDs: 17502484 19038683 17150190
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mononuclear cells PMIDs: 20668107 19761394 22834565 21596713

Cochrane evidence based reviews: heart failure

Genetic Tests for Congestive Heart Failure

Genetic tests related to Congestive Heart Failure:

# Genetic test Affiliating Genes
1 Congestive Heart Failure 29

Anatomical Context for Congestive Heart Failure

MalaCards organs/tissues related to Congestive Heart Failure:

Heart, Kidney, Testes, Lung, Endothelial, Breast, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Congestive Heart Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
2 Lateral Plate Mesoderm Splanchnic Mesoderm Pericytes Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Congestive Heart Failure

Articles related to Congestive Heart Failure:

(show top 50) (show all 54425)
# Title Authors PMID Year
Provider adherence to clinical guidelines related to lipid-lowering medications. 9 38
20180482 2010
Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. 9 38
20128603 2010
Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. 9 38
18760492 2010
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. 9 38
19763821 2010
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 9 38
20391898 2010
Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. 9 38
19666591 2009
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 9 38
19560695 2009
The clinical pharmacology of eplerenone. 9 38
19379127 2009
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. 9 38
19269262 2009
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. 9 38
19327624 2009
[The cardiorenal syndrome and optimal treatment of renal anemia]. 9 38
19370853 2009
Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure. 9 38
19293536 2009
Porous silicon affinity chips for biomarker detection by MALDI-TOF-MS. 9 38
18948066 2008
Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. 9 38
17662495 2008
Effect of erythropoietin in a patient with severe congestive heart failure--a case report. 9 38
18756924 2008
[Serum levels of fatty acid-binding protein and brain natriuretic peptide in children with pneumonia complicated by acute congestive heart failure]. 9 38
18554454 2008
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. 9 38
18458262 2008
Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. 9 38
19804290 2008
Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 9 38
18446719 2008
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. 9 38
18219303 2008
Accuracy of the isovolumic relaxation time in the emergency diagnosis of new-onset congestive heart failure with preserved left ventricular systolic function in the setting of B-type natriuretic peptide levels in the mid-range. 9 38
17395301 2008
B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. 9 38
18347270 2008
A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. 9 38
18021271 2008
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. 9 38
18953278 2008
Clinical correlates of very high brain natriuretic peptide levels in hospitalized patients. 9 38
18256556 2008
The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. 9 38
19128227 2008
[The role of urotensin II in human pathophysiology]. 9 38
19323069 2008
Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. 9 38
17967592 2007
Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case? 9 38
17382416 2007
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. 9 38
17923351 2007
Aldosterone and end-organ damage. 9 38
17683282 2007
ANP is cleared much faster than BNP in patients with congestive heart failure. 9 38
17479256 2007
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments. 9 38
17452702 2007
Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. 9 38
17456069 2007
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. 9 38
17361123 2007
The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients. 9 38
17452135 2007
Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. 9 38
17223209 2007
AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. 9 38
17452134 2007
Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. 9 38
17083971 2007
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 9 38
17345160 2007
Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies. 9 38
17511350 2007
Discovery of new cardiovascular hormones for the treatment of congestive heart failure. 9 38
17346128 2007
Brain natriuretic peptide plasma level is a reliable indicator of advanced diastolic dysfunction in patients with chronic heart failure. 9 38
16476572 2007
Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure. 9 38
18767410 2007
Brain natriuretic peptide--the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. 9 38
17694799 2007
[Genetic polymorphism of beta-adrenergic receptors and mortality in ischemic heart disease]. 9 38
17374341 2007
Analytical and clinical performance of three natriuretic peptide tests in the emergency room. 9 38
17484634 2007
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 9 38
16870827 2007
Aquaporins as targets for drug discovery. 9 38
17692010 2007
[Plasma urotensin II level in patients with chronic congestive heart failure]. 9 38
18634521 2006

Variations for Congestive Heart Failure

ClinVar genetic disease variations for Congestive Heart Failure:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ABCC8 NM_000352.5(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic rs1344172059 11:17452385-17452385 11:17430838-17430838
2 ABCC8 NM_000352.5(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 11:17426099-17426099 11:17404552-17404552
3 VCL NM_014000.2(VCL): c.1490T> C (p.Ile497Thr) single nucleotide variant Uncertain significance rs572757800 10:75854166-75854166 10:74094408-74094408

Expression for Congestive Heart Failure

Search GEO for disease gene expression data for Congestive Heart Failure.

Pathways for Congestive Heart Failure

GO Terms for Congestive Heart Failure

Cellular components related to Congestive Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 REN NPPC NPPB NPPA KNG1 EDN1
2 myosin filament GO:0032982 9.32 MYH7 MYH6
3 extracellular region GO:0005576 9.32 VCL TTN REN NPPC NPPB NPPA
4 muscle myosin complex GO:0005859 9.26 MYH7 MYH6
5 sarcomere GO:0030017 9.13 TTN MYH7 MYH6

Biological processes related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.92 NPPC NPPA EDN1 ADM
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.92 KNG1 EDN1 AGTR1 ADM
3 kidney development GO:0001822 9.88 REN MME AGTR1 ACE
4 muscle contraction GO:0006936 9.88 VCL TTN MYH7 MYH6
5 female pregnancy GO:0007565 9.82 NPPA ADRA2C ADM
6 cardiac muscle contraction GO:0060048 9.79 TTN MYH7 MYH6
7 regulation of cardiac conduction GO:1903779 9.77 NPR1 NPPC NPPA
8 muscle filament sliding GO:0030049 9.77 TTN MYH7 MYH6
9 positive regulation of heart rate GO:0010460 9.74 NPPA EDN1 ADM
10 cGMP-mediated signaling GO:0019934 9.73 NPR1 NPPC NPPA
11 regulation of the force of heart contraction GO:0002026 9.72 MYH7 MYH6 ADM
12 striated muscle contraction GO:0006941 9.71 TTN MYH7 MYH6
13 cardiac muscle hypertrophy in response to stress GO:0014898 9.7 NPPA MYH7 MYH6
14 positive regulation of urine volume GO:0035810 9.69 NPR1 NPPB EDN1
15 positive regulation of renal sodium excretion GO:0035815 9.67 NPR1 NPPB EDN1
16 regulation of vasoconstriction GO:0019229 9.67 EDN1 AGTR1 ADRA2C ACE
17 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.66 ADRB1 ADRA2C
18 response to muscle stretch GO:0035994 9.66 NPPA EDN1
19 cardiac muscle fiber development GO:0048739 9.65 TTN MYH6
20 negative regulation of blood coagulation GO:0030195 9.65 KNG1 EDN1
21 adult heart development GO:0007512 9.65 MYH7 MYH6
22 amyloid-beta metabolic process GO:0050435 9.65 REN MME ACE
23 regulation of vascular permeability GO:0043114 9.64 NPR1 NPPB
24 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.63 AGTR1 ACE
25 angiotensin maturation GO:0002003 9.63 REN MME ACE
26 regulation of blood vessel diameter GO:0097746 9.62 NPR1 NPPB AGTR1 ACE
27 renin-angiotensin regulation of aldosterone production GO:0002018 9.61 REN AGTR1
28 body fluid secretion GO:0007589 9.61 NPR1 NPPB EDN1
29 positive regulation of cGMP-mediated signaling GO:0010753 9.58 NPR1 NPPC NPPA
30 receptor guanylyl cyclase signaling pathway GO:0007168 9.56 NPR1 NPPC NPPB NPPA
31 regulation of blood pressure GO:0008217 9.5 REN NPR1 NPPB NPPA MYH6 EDN1
32 cGMP biosynthetic process GO:0006182 9.46 NPR1 NPPC NPPB NPPA
33 regulation of blood vessel size GO:0050880 9.1 NPR1 NPPC NPPB NPPA KNG1 EDN1
34 G protein-coupled receptor signaling pathway GO:0007186 10.18 NPR1 KNG1 EDN1 AGTR1 ADRB1 ADRA2C

Molecular functions related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 actin filament binding GO:0051015 9.71 VCL TTN MYH7 MYH6
2 endopeptidase activity GO:0004175 9.65 REN MME ACE
3 hormone activity GO:0005179 9.55 NPPC NPPB NPPA EDN1 ADM
4 microfilament motor activity GO:0000146 9.51 MYH7 MYH6
5 signaling receptor binding GO:0005102 9.5 REN NPPC NPPB NPPA KNG1 EDN1
6 adrenergic receptor activity GO:0004935 9.49 ADRB1 ADRA2C
7 actin-dependent ATPase activity GO:0030898 9.46 MYH7 MYH6
8 epinephrine binding GO:0051379 9.43 ADRB1 ADRA2C
9 exopeptidase activity GO:0008238 9.37 MME ACE
10 alpha-2A adrenergic receptor binding GO:0031694 9.32 ADRB1 ADRA2C
11 bradykinin receptor binding GO:0031711 9.26 AGTR1 ACE
12 hormone receptor binding GO:0051427 8.8 NPPC NPPB NPPA